Clinical Trial Update: Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a depot-formulated subcutaneous immunotherapy for house dust mite–sensitized allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Depot-formulated subcutaneous immunotherapy

Snippet

Sponsor: Roxall Medicina España S.A | Conditions: Allergic Rhinoconjunctivitis | Phase 1 | Status: COMPLETED